Full Title
A BLUEPRINT of Haematopoietic Epigenomes

Fp7 – Health - Collaborative project

Contract Number

In response to the call for a high impact initiative on the human epigenome, the BLUEPRINT Consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukaemic counterparts. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by IHEC. This resource-generating activity will be conducted at dedicated centres to be complemented by confederated hypothesis-driven research into blood-based diseases, including common leukaemias and autoimmune disease (T1D), by epigenetic targets and compound identification, and by discovery and validation of epigenetic markers for diagnostic use.
By focussing on 100 samples of known genetic variation BLUEPRINT will complete an epigenome-wide association study, maximizing the biomedical relevance of the reference epigenomes. Key to the success of BLUEPRINT will be the integration with other data sources (i.e. ICGC, 1000 genomes and ENCODE), comprehensive bioinformatic analysis, and user-friendly dissemination to the wider scientific community. The involvement of innovative companies will energize epigenomic research in the private sector by creating new targets for compounds and the development of smart technologies for better diagnostic tests.
BLUEPRINT will outreach through a network of associated members and form critical alliances with leading networks in genomics and epigenomics within Europe and worldwide. Through its interdisciplinarity and scientific excellence combined with its strong commitment to networking, training and communication BLUEPRINT strives to become the cornerstone of the EU contribution to IHEC.

54 months (01/10/2011 - 31/03/2016)

Project Funding
29,996,664.00 €

Radboud University Nijmegen, Netherlands
Faculty of Science, Department of Molecular Biology
Prof. Hendrik G. Stunnenberg
Phone: +31 243510524


  • University College London, United Kingdom (Prof. Stephan Beck/ Prof. Tariq Enver)
  • University of Cambridge, United Kingdom (Prof. Anne Ferguson?Smith/ Prof. Willem H. Ouwehand)
  • Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (Dr. Dirk Schübeler)
  • Christian Albrechts University Kiel, Germany (Prof. Reiner Siebert)
  • Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Prof. Alfonso Valencia)
  • European Institute of Oncology, Milan, Italy (Prof. Pier Giuseppe Pelicci/ Saverio Minucci)
  • European Bioinformatics Institute, United Kingdom (Dr. Paul Flicek)
  • Wellcome Trust Sanger Institute, United Kingdom (Prof. Michael Stratton/ Dr. David Adams/ Dr. Nicole Soranzo)
  • Bellvitge Institute for Biomedical Research, Spain (Dr. Manel Esteller)
  • Centro Nacional de Análisis Genómico, Spain  (Dr. Ivo Gut)
  • Max Plack Institute for Bioinformatics, Germany (Prof. Thomas Lengauer)
  • Max Planck Institute for Molecular Genetics, Berlin, Germany (Prof. Hans Lehrach/ Prof. Martin Vingron)
  • Saarland University, Saarbrücken, Germany (Prof. Jörn Walter)
  • Second University of Naples, Italy (Prof. Lucia Altucci)
  • Centre for Genomic Regulation, Barcelona, Spain (Prof. Xavier Estivill/ Prof. Roderic Guigó/ Prof. Thomas Graf
  • Queen Mary University of London, United Kingdom (Prof. David Leslie  Dr. Jude Fitzgibbon/ Dr. Vardhman Rakyan
  • The Babraham Institute, Cambridge, United Kingdom (Wolf Reik)
  • Cellzome AG, Heidelberg, Germany (Dr. David Simmons)
  • Diagenode SA, Liége, Belgium (Didier Allaer)
  • Halo Genomics AB, Uppsala, Sweden (Dr. Fredrik Dahl)
  • Genomatix Software GmbH, München, Germany (Dr. Martin Seifert)
  • Oxford Nanopore Technologies Ltd, Oxford, United Kingdom (Dr. Spike Willcocks)
  • Siena Biotech SpA, Italy (Dr. Andrea Caricasole)
  • Centre of Immunology of Marseille-Luminy, France (Dr. Salvatore Spicuglia)
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Dr. Elías Campo)
  • Weizmann Institute of Science, Israel (Dr. Amos Tanay)
  • Erasmus University Medical Center, Rotterdam, Netherlands (Dr. Frank Grosveld)
  • University of Ulm, Germany (Prof. Bernhard O. Boehm)
  • University of Edinburgh, UK (Prof. Adrian Bird)
  • Lund University, Sweden (Prof. Åke Lernmark Hendrik)
  • University of Copenhagen, Denmark (Prof. Kristian Helin)
  • Sapienza University of Rome, Italy (Prof. Antonello Mai)
  • Vivia Biotech, S.L., Madrid, Spain (Dr. Juan Ballesteros)
  • University of Geneva, Switzerland (Prof. Emmanouil Dermitzakis/ Prof. Stylianos E. Antonarakis)
  • University Medical Center Groningen, Netherlands (Prof. Edo Vellenga)
  • CNRS – UMR 814 and Paris Descartes University, Paris (Dr. Elizabeth Macintyre)
  • Universitätsklinikum Essen, Germany (Dr. Ralf Küppers)
  • University Leipzig, Germany (Prof. Markus Loeffler)
  • Barcelona Supercomputing Center, Barcelona, Spain (David Torrents)
  • Sigolis AB, Uppsala, Sweden (Dr. Jonas Jarvius)
  • European Research and Project Office GmbH, Saarbrücken, Germany (Dr. Vera Schneider)
Contact at Eurice
  • Melanie Haupenthal
  • Project Officer
  • Phone: +49 681 95923381

Project Website